This section is about issues of intellectual property in pharmaceutical industry.
Contributions from members are very welcome. Every article is published with full credentials of Author. Please Register as the member and submit your article.
Intellectual Propriatery News
Written by Jesse Tale
Wednesday, 06 September 2006
Avandia® Patents Afford Protection Against Generic Competition
Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb.
MUMBAI: Pharmaceutical company Lupin on Thursday said a district court in the US has ruled against the company in a patent infringement suit filed by Sanofi-Aventis and King Pharmaceuticals.
Full Story of Relpax Patent Protection Not Told by Orange Book?
Pfizer’s oral anti-migraine medicine Relpax, (Eletriptan hydrobromide) appears to have more patent protection than meets the eye. A report by GenericsWeb has uncovered an array of patent protection in terms of molecular form, active ingredient synthesis, formulations and medical use on not only the commercial product but also on potential commercial alternatives for generic competitors.
How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories
Use this handy guide to navigate the calculation of patent expiry dates in US, Canada, Germany, Spain, France, United Kingdom and Australia, and also data exclusivity in the US, Canada, Europe and Australia.
One form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ...
Information provided by European Generic Association.
Strategies for early generic launch - Atorvastatin
The major constraining patent for Atorvastaitn is EP-00247633. Patentee is Warner-Lambert company. Priority date is 30 May 1986. SPC for EP-00247633 will expire in Nov. 2011 in number of EU countries. However, in Slovenia, Czech R., Bulgaria, Hungary, Poland and Slovakia there is no national patents with link to EP-00247633 as primary patent.
Strategies for successful generic launch in European Union - Sildenafil case
The experts of Framvita.Net have made an brief analysis of current status of intellectual property and generic products about sildenafil. This article may help you in planning of successful launch of generic sildenafil in European Union.
FarmavitaR+ Journal 
The major constraining patent for Atorvastaitn is EP-00247633. Patentee is Warner-Lambert company. Priority date is 30 May 1986. SPC for EP-00247633 will expire in Nov. 2011 in number of EU countries. However, in Slovenia, Czech R., Bulgaria, Hungary, Poland and Slovakia there is no national patents with link to EP-00247633 as primary patent.
